Track market-moving stories before they get noisy

Carnival Corp (NYSE:CCL) shares fell almost 6% on Tuesday after the cruise operator issued a third quarter profit outlook below Wall Street expectations, overshadowing stronger-than-expected second-quarter results and record revenue.

The company reported adjusted earnings of $0.41 per share for the quarter ended May 31, ahead of analysts' estimates of $0.33 per share.

Revenue rose to a record $6.7 billion, slightly above the consensus forecast of $6.68 billion.

Net income attributable to Carnival reached $537 million, while adjusted net income climbed more than 20% year over year to a record $569 million. Adjusted EBITDA also hit a record $1.6 billion.

Carnival said customer deposits reached an all-time high of $9 billion, up more than $450 million from the previous year's record, while bookings for the remainder of 2026 remain ahead of last year at historically high prices.

For the third quarter, Carnival expects adjusted earnings of $1.35 per share, below analysts' expectations of $1.42. The company projected full-year 2026 adjusted earnings of $2.22 per share, also below the consensus $2.23.

Carnival CEO Josh Weinstein said the company delivered its "twelfth consecutive quarter of record net yields" despite "extreme geopolitical headwinds and nearly 30% higher fuel costs."

The company said booking trends for Mediterranean itineraries were affected by the prolonged conflict in the Middle East, prompting it to prioritize pricing over occupancy. Carnival noted that it is 93% booked for 2026, with less inventory remaining for sale than at the same point last year.

Weinstein said recent booking trends indicate the company is beginning to see "a reversal of these headwinds," adding that demand for 2027 and beyond continues to run ahead of prior-year levels.

For 2026, Carnival expects net yields to increase about 3.2% from 2025 levels and adjusted cruise costs excluding fuel per available lower berth day to rise approximately 3.7%. The company said elevated logistics costs linked to disruptions from the Middle East conflict are incorporated into its outlook.

Synopsys (NASDAQ:SNPS | SNPS Price Prediction) is one of the most strategically positioned software franchises in the AI-era semiconductor stack, and the recent pullback has reset the setup for investors evaluating the name.

The 24/7 Wall St. price target for Synopsys is $561.40, implying 23.25% upside from $455.51. Our model classifies SNPS as a high-conviction setup, with 90% confidence in the target.

24/7 Wall St. Price Target Summary Metric Value Current Price $455.51 24/7 Wall St. Price Target $561.40 Upside 23.25% Recommendation BUY Confidence 90% A Strong Quarter Met With a Sleepy Stock SNPS is down 7.77% over the past month and 3.03% year to date, trading 14% below its 52-week high of $651.73 and well off the low of $376.18.

The cooldown followed a strong Q2 FY26 print on May 27, 2026: revenue of $2.276B, up 42% YoY, with non-GAAP EPS of $3.35 beating estimates by 5.96%. Design Automation operating margin expanded to 43.3% from 40.9% a year earlier. Management raised FY26 guidance to $9.625B to $9.705B in revenue and $14.72 to $14.80 in non-GAAP EPS.

  The Case for $667 and Beyond Bulls have a clean thesis. CEO Sassine Ghazi said on the Q2 call that “AI is scaling semiconductor demand, architectural diversity and complexity of chips and the systems they power, driving demand across our portfolio.”

Synopsys sits at the choke point for every advanced-node design, and the $35 billion Ansys acquisition that closed July 17, 2025 extends that moat into multi-physics simulation.

Q1 FY26 revenue grew 65.4% YoY, and the backlog stood at $11.4B exiting FY25. Of 25 analysts, 17 rate the stock Buy or Strong Buy against just one Strong Sell. Our bull case scenario puts SNPS at $667.14 within 12 months, a 46.46% return, if Ansys synergies accelerate and the September 30 Investor Day reveals raised long-term targets.

The Risks Worth Watching The bear case starts with the balance sheet. SNPS carries roughly $10B in long-term debt and $403.6M in quarterly intangibles amortization, which crushed GAAP net income to $17.1M in Q2.

Bulls will counter that this is purely a non-cash artifact of purchase accounting and that non-GAAP EPS and free cash flow of $2B tell the real story. Design IP remains soft, with management divesting Processor IP Solutions, and export controls into China remain an overhang.

Year-over-year quarterly earnings growth of -0.96% trimmed our factor by 0.03. The bear scenario lands the stock at $494.55 over the next year, still 8.57% above today.

Synopsys Price Prediction 2026-2030 The 24/7 Wall St. price target of $561.40 reflects a high-confidence buy. The tipping factor is the disconnect between accelerating non-GAAP fundamentals and a stock that has gone nowhere YTD.

The bull case rests on AI-driven design complexity remaining a multi-year tailwind and Ansys synergies landing as guided. The bear case strengthens if the trailing P/E of 104 matters more than the forward P/E of 31, or if China export controls tighten further.

Looking further out, here is where our model projects SNPS could trade, assuming current growth and margin trajectories hold.

Year 24/7 Wall St. Price Target 2026 $561.40 2027 $666.63 2028 $710.01 2029 $805.26 2030 $849.44 These projections assume Synopsys keeps executing on Ansys integration and AI design demand stays robust. Significant upside or downside could come from China export policy, EDA pricing power, or the pace of advanced-node design starts.

Oracle Corp (NYSE:ORCL, XETRA:ORC) has reduced its workforce by about 21,000 employees over the past year, citing the deployment of artificial intelligence technologies across its operations, according to its annual filing.

The software and cloud company employed approximately 141,000 full-time workers as of May 31, 2026, compared with about 162,000 a year earlier, a decline of nearly 13%.

"The adoption and deployment of AI technologies across our operations have resulted, and may continue to result, in reductions to our workforce," Oracle said in the filing.

Oracle reported $1.8 billion in restructuring costs during the fiscal year, including severance payments and other exit expenses, up from $374 million in the prior year.

The company noted that workforce reductions can be disruptive and may lead to lower productivity, shortages of skilled employees in some roles, loss of institutional knowledge, and weaker employee morale and retention.

Oracle had informed employees in March that it planned to eliminate thousands of positions as it faced investor scrutiny over increased borrowing to support its AI infrastructure expansion. In January, the company announced plans to raise $50 billion through debt and equity financing.

Capital expenditures rose 162% in the latest fiscal year to $55.7 billion, while free cash flow was negative $23.7 billion.

Shares of Oracle traded down almost 3% at Tuesday’s opening bell, down about 13% so far this year.

Secures Two-Gigawatt Development Site in Kansas City Metro, and Plans to Increase Teraco Ownership and to Acquire Columbia Capital June 22, 2026 07:00 ET  | Source: Digital Realty Trust, L.P.

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced a series of transactions that together bolster the company’s three core pillars of growth: (i) expansion of its hyperscale data center development capacity through the acquisition of a new powered land site in the Kansas City metro, (ii) growth of its colocation and connectivity portfolio through the purchase of certain minority shareholder stakes in Teraco, and (iii) further scaling of its Strategic Private Capital platform through the acquisition of Columbia Capital a leading investment firm in the digital infrastructure space.

Expansion into Kansas City Market
Digital Realty has acquired approximately 1,440 acres of land at Astra Enterprise Park, located near Kansas City to support hyperscale data center development for approximately $475 million(1) in cash and common units in its operating partnership. The acquisition marks an entry into a Top 30 U.S. metro with fast-growing technology sector exposure, ample utility and telecommunications infrastructure, and strong connectivity fundamentals. According to datacenterHawk, the Kansas City metro is the 7th largest data center market in the U.S., when including capacity that is currently under construction and in planning.

To support development of the site, Digital Realty has entered into an Energy Service Agreement with the local utility to provide 600 megawatts of utility power by early 2028, rising to two gigawatts at full delivery.

Increase in Teraco Ownership
As part of the continued investment in its colocation and connectivity platform, Digital Realty is increasing its ownership interest in Teraco, Africa’s leading data center platform, to 77% through the acquisition of shares from certain minority shareholders. Digital Realty will purchase the 16% stake for approximately $650 million(1), principally via the issuance of 3.4 million shares of common stock.

Teraco represents a key component of Digital Realty’s global colocation and connectivity footprint, with a portfolio of highly connected, network-dense campuses serving a growing base of customers across the EMEA region.

Acquisition of Columbia Capital
Digital Realty plans to acquire Columbia Capital for approximately $485 million(1), principally through the issuance of 2.3 million shares of common stock, with a lockup that releases over a multi-year period and an earnout that is subject to certain performance hurdles. Founded in 1989, Columbia Capital is focused on the communications,   technology and digital infrastructure space, with over $9 billion in fund commitments from hundreds of investors, including sovereign wealth funds, pension funds, insurance companies, endowments and other institutional investors.

The acquisition will accelerate Digital Realty’s Strategic Private Capital platform and provides increased expertise and visibility into adjacent digital infrastructure sectors. Columbia Capital’s experienced investment team and established portfolio complement Digital Realty’s global operating platform and will strengthen investment capabilities to take advantage of the expanding AI infrastructure ecosystem.

Columbia Capital and Digital Realty have collaborated on multiple digital infrastructure projects. Columbia is a long-time co-investor in Teraco whose involvement predates Digital Realty’s acquisition of a majority interest in August 2022. The two companies have also partnered through Vela Infrastructure, a subsea cable landing station developer.

Executive Commentary
“These transactions support the continued momentum of Digital Realty’s three core pillars of growth. The purchase of land in the Kansas City metro enhances our ability to serve hyperscale customers’ near term requirements, while our increased stake in Teraco strengthens our position in Africa’s leading data center platform and supports the continued growth of our global colocation and connectivity business,” said Andy Power, President and Chief Executive Officer of Digital Realty. “Our history of collaboration with Columbia Capital reflects a shared long-term perspective while providing additional flexibility to support the scaling of both our hyperscale development pipeline and our private capital platform.”

"Taken together, these transactions are expected to further enhance Digital Realty's growth profile, while maintaining our balance sheet discipline and positioning the company for the continued investment opportunity we see ahead," said Matt Mercier, Chief Financial Officer of Digital Realty. These investments will be principally funded through the issuance of 6.3 million shares of common stock (and operating partnership units) at a weighted average price of $197.54 per share (or unit).

The Teraco and Columbia Capital transactions are expected to close in the second half of 2026 and remain subject to customary closing conditions.

Additional Resources

De Soto data center projectProject Sediba: Teraco's renewable energy milestoneThe PERE Podcast: Andy Power discusses the strategic importance of Private Capital to Digital Realty About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives customers access to the connected data communities that matter to them through a global footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more, visit digitalrealty.com or follow us on LinkedIn and X.

Safe Harbor Statement
This press release contains forward-looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties which may cause actual results to differ materially from those described. These include statements related to the Fund, customer demand, expected benefits, use of proceeds, and the company’s strategy. For a description of these risks and uncertainties, please refer to the company’s filings with the U.S. Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.

1 Based on closing stock price of $188.15/sh as of June 18, 2026.

Take-Two Interactive Software Inc (NASDAQ:TTWO) shares could see a stronger long-term monetization profile from the next iteration of Grand Theft Auto Online (GTAO), according to Bank of America, which raised its price objective on the stock and upgraded its forward bookings assumptions for the franchise.

Bank of America reiterated its 'Buy' rating on Take-Two and raised its price objective to $368, based on a 26x multiple applied to its FY28 earnings estimate. The firm characterized this as a peak valuation scenario, with potential for further upward revisions if GTAO monetization exceeds expectations.

The firm increased its financial year 2028 GTAO bookings forecast by roughly $900 million to $2.2 billion, lifting its assumed annual revenue per monthly active user (MAU) to $60 from $35 previously.

The revision reflects expectations that the next version of GTAO could monetize at nearly twice the rate of its predecessor, narrowing the gap with leading live-service titles such as Fortnite.

The analysts argued that GTAO currently under-monetizes relative to comparable franchises, and expect the next installment to close that disparity as its “pay-to-progress” structure encourages higher average player spending than Fortnite’s cosmetics-driven model. Bank of America also noted that Grand Theft Auto VI’s player base is likely to carry higher lifetime value than the broader free-to-play audience seen in other major live-service ecosystems.

At the high end of the estimate range, the firm pointed to monetization levels above $100 per MAU in heavily “pay-to-win” sports titles, suggesting additional upside if engagement trends skew more aggressively toward in-game spending.

Bank of America left its financial year 2027 estimates unchanged, citing a likely late-year ramp for GTAO’s contribution. It now forecasts financial year 2028 net bookings of $10.7 billion and earnings per share of $14.23.

Beyond revenue assumptions, the report highlighted structural improvements at Rockstar that could support stronger monetization. These include a more robust content pipeline, enhanced anti-cheat systems, and a substantially larger live-service team, expanded to more than 100 staff compared with roughly 10 at GTAO’s 2013 launch. The analysts believes that these changes address early limitations that previously constrained long-term engagement and spending.

The bank’s analysts also suggested that GTAO’s current iteration, which generates an estimated $400 million in annual bookings versus a peak of around $700 million in 2021, underscores the room for growth in a more modernized live-service framework.

Bank of America estimates that the next GTAO could support more than 40 million sustainable MAUs, potentially placing it among the largest live-service franchises globally, behind only Fortnite.

Take-Two shares traded up 2% at $244 on Tuesday afternoon.

Snowflake Inc (NYSE:SNOW) remains well-positioned despite intensifying competition from Databricks, with Jefferies analysts writing that both companies are benefiting from growing enterprise demand for data and artificial intelligence infrastructure and have room to expand.

Jefferies noted that Databricks' annualized revenue run rate is on track to exceed $6.9 billion in the first half of fiscal 2027, representing about 65% year-over-year growth in its core business and roughly 80% growth including large language model monetization.

By comparison, the firm estimates Snowflake's revenue run rate at approximately $5.5 billion, growing 32% year over year.

The analysts wrote that Databricks is poised to surpass Snowflake in scale for the first time, though Snowflake maintains stronger profitability, generating free cash flow margins of around 23% while Databricks remains near breakeven.

Jefferies highlighted that Snowflake has accelerated growth over the past two quarters despite rising competition, delivering roughly four percentage points of product revenue acceleration in the first quarter of fiscal 2027 to 34% year-over-year growth.

The firm wrote that Snowflake's AI offerings, including CoCo and Snowflake CoWork, could drive additional monetization opportunities and increase consumption of its core data platform.

Databricks has also expanded its data warehousing business, with its SQL Warehouse product surpassing a $1.5 billion annualized revenue run rate. However, Jefferies wrote that Snowflake still has a materially larger data warehousing business and has significantly narrowed the technical gap over the past year, particularly in AI capabilities.

The analysts added that Databricks' Genie platform could help broaden AI adoption among business users by enabling employees to access and interact with enterprise data through integrations with applications such as Microsoft Teams, Slack and Google Drive.

Shares of Snowflake closed at about $235 on Wednesday, having gained about 7% so far this year.

Costco Wholesale (NASDAQ: COST | COST Price Prediction) trades near $985, a price that demands flawless execution into a tightening macro even as the best-in-class compounder narrative remains intact. Kevin Warsh’s first meeting as Fed Chair lands with sticky inflation keeping long yields elevated, and high-multiple stocks have already started bleeding multiple compression into premium consumer staples.

Costco runs a membership-warehouse model that turns fee income into low prices, with Kirkland Signature and Costco Logistics extending the moat. The flywheel produced $275.24B in FY25 revenue and $18.21 in EPS, with $13.34B in operating cash flow.

After climbing 14.74% YTD to $986.68, COST has given back 5.94% over the past month as the market reprices the multiple a slow-and-steady retailer deserves when 10-year yields refuse to budge.

The Flywheel Keeps Spinning Faster Than the Share Price Q3 FY26 delivered EPS of $4.93 on revenue of $70.53B, an 11.6% YoY jump beating consensus, with digitally-enabled comparable sales up 21.5% and e-commerce traffic up 37%. Membership fee income grew 10.7% to $1.37B, the worldwide renewal rate held at 89.7%, and executive members now drive 75.0% of net sales. Net income jumped 15.2%.

Management plans to reach roughly 940 warehouses by FY26 year-end. Quarterly earnings growth running at 45.5% YoY makes a forward P/E of 44 look less absurd in context. Analyst sentiment broadly agrees, with 22 of 37 analysts rating it Buy or Strong Buy.

A 49 P/E Meets a Fed That Cannot Cut Fast Enough Costco trades at a trailing P/E of 49, a forward P/E of 44, and 13 times book, with a PEG of 4.8. For a 3% net margin retailer, that pricing assumes years of uninterrupted execution. Vanguard’s 2026 outlook warns core inflation likely stays above 2.5%, leaving the Fed limited scope to cut below a 3.5% neutral rate. Sticky inflation plus elevated long yields compresses premium multiples.

COST trades below its 50-day moving average of $1,004.25 and only modestly above the 200-day at $957.56, with a 52-week high of $1,096.50 already in the rearview.

Great Business, Demanding Entry Price Nothing in the fundamentals justifies selling a compounder with 82.1M paid memberships and double-digit fee growth. The multiple does not justify chasing the stock into Warsh’s first meeting. A pullback into the low-$900s, or a broader market reset toward $830, would offer real margin of safety. Watch comp sales, membership growth (now running near 4.1%), and any dovish signal from the Fed.

Where the Numbers Leave Costco Today Costco currently trades at $986.68, up 14.74% YTD versus a 10.03% gain for the S&P 500, but down 5.94% over the past month. The consensus analyst target of $1,082.33 implies roughly 10% upside. Across 37 covering analysts:

Strong Buy: 3 Buy: 19 Hold: 13 Sell: 1 Strong Sell: 1 Valuation runs hot with EV/EBITDA at 29 and a 0.55% dividend yield, against a market cap of $434.4B.

At $985, Patience Has a Price Tag At $985, Costco sits in a tension zone. The business fires on every cylinder that matters, yet the entry price assumes the macro cooperates and the multiple holds, both of which look uncertain with Warsh inheriting a sticky inflation problem and the market already punishing high multiples.

The bull case strengthens if Costco pulls back toward $830 on broader multiple compression, or if comps reaccelerate above 10% adjusted while the Fed signals real cuts. The bear case requires a real crack in the 89.7% renewal rate or membership growth, which Q3 did not show. Until one of those breaks, the setup remains in stalemate.

The cost of patience is missing the drift to consensus. The cost of acting is paying 44 times forward earnings for a 3% margin retailer into a tightening cycle. That asymmetry explains why many investors are sitting on their hands at this price.

Key Takeaways Costco's membership model is strengthening through deeper engagement, not just member additions.Executive members rose 9.6% year over year to 41.2 million and accounted for 75% of sales.Membership fee income climbed 10.7% to $1.37B, with renewals strong in the U.S., Canada and globally. Costco Wholesale Corporation’s (COST - Free Report) membership model appears to be gaining strength not simply through member additions, but through deeper engagement. The latest quarter saw high renewal rates, rising executive membership penetration and solid membership income growth, suggesting member loyalty remains intact.

Membership fee income increased 10.7% year over year to $1,373 million during the third quarter of fiscal 2026. While part of the gain reflected the membership fee increase implemented in September 2024, management noted that membership income still grew 7%, excluding the fee increase and foreign exchange impacts, driven by member growth and executive membership upgrades.

The most notable development was the continued expansion of executive memberships. Executive members reached 41.2 million at quarter-end, up 9.6% from the prior year, far outpacing overall paid membership growth of 4.1%. The company also launched its executive membership program in China and reported stronger-than-expected early adoption. Executive members accounted for 75% of sales, underscoring their importance to the overall membership ecosystem.

Management emphasized that executive members typically shop more often and spend more than standard members, making this mix shift particularly meaningful for the overall membership ecosystem.

Renewal metrics also remained exceptionally strong. Costco reported a 92.2% renewal rate in the United States and Canada and an 89.7% renewal rate worldwide. Management highlighted that targeted digital communication and retention initiatives helped offset pressure from the growing mix of online sign-ups, which historically renew at lower rates.

Taken together, rising executive penetration, resilient renewals and sustained membership income growth indicate that Costco is not only retaining members effectively but also increasing the value it derives from each membership relationship.

Walmart & BJ’s Wholesale: Membership Momentum Remains StrongCostco is not the only retailer benefiting from a stronger membership ecosystem. Walmart Inc. (WMT - Free Report) continues to deepen engagement through Walmart+, with membership fee revenues rising 17.4% globally in the first quarter and Walmart+ recording a record level of net additions. Management noted that membership has become an increasingly important profit stream, with members spending significantly more than non-members and utilizing benefits such as fuel savings and faster delivery.

BJ's Wholesale Club Holdings, Inc. (BJ - Free Report) reported robust membership trends. Membership fee income increased 9.9% year over year to a record $132.4 million, supported by strong member acquisition, retention and higher-tier membership penetration. Management emphasized that higher-tier members remain more engaged, shop more frequently and generate greater lifetime value.

Like Costco, both Walmart and BJ’s Wholesale are demonstrating that a growing base of loyal, higher-value members can drive recurring revenues, stronger engagement and long-term sales growth.

What the Latest Metrics Say About CostcoCostco has seen its shares tumble 1.4% over the past three months against the industry’s growth of 2.2%. 
 

Image Source: Zacks Investment Research

From a valuation standpoint, Costco's forward 12-month price-to-earnings ratio stands at 43.14, higher than the industry’s ratio of 31.26. However, it is trading below its 12-month median level of 46.55, indicating some moderation in valuation despite sustained investor confidence in the stock.
 

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Costco’s current financial-year sales and earnings per share implies year-over-year growth of 9.4% and 13.3%, respectively. For the next fiscal year, the consensus estimate indicates a 7.8% rise in sales and 10.2% growth in earnings.

The consensus estimate for earnings per share for the current and next fiscal year has increased by 5 cents and 6 cents to $20.38 and $22.46, respectively, over the past 30 days.

Image Source: Zacks Investment Research

Costco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

-

Launching today on Microsoft 365 Copilot Cowork, with availability expanding across compatible AI platforms

NEW YORK--(BUSINESS WIRE)--Moody’s Corporation (NYSE: MCO) today announced the release of its first set of AI skills – purpose-built, platform-agnostic instruction kits that encode Moody’s analytical frameworks and connect AI agents to its decision-grade intelligence. Available across compatible AI platforms beginning with Microsoft 365 Copilot Cowork, Moody’s skills enable customers to execute complex analytical workflows through a single natural-language request, with outputs grounded in Moody’s proprietary ratings, research, and risk intelligence.

“Moody’s is among the first financial data providers to deliver a full library of skills on an open standard, and today’s launch is just the beginning,” said Cristina Pieretti, Head of Digital Content and Innovation at Moody’s. “AI platforms are becoming the interface for financial decision-making, and the next phase of adoption will be defined by execution. Skills are how we encode Moody’s expertise into that execution layer.”

Skills are emerging as the standard for how AI agents execute specialist work. By publishing its analytical frameworks as skills that run on the platforms where market participants already build and operate, Moody’s is embedding its decision-grade intelligence at the center of how financial analysis is executed across the industry.

Moody’s first wave of skills covers high-priority financial workflows where Moody’s expertise is most concentrated:

Earnings Call Summary – Summarizes earnings call transcripts, covering revenue trends, pricing dynamics, consumer health, tariff exposure, and more. Peer Analysis – Produces an investor-grade comparison across leverage, profitability, ESG, credit quality, and more. Public Information Book – Builds a comprehensive dossier on a single entity, spanning financials, governance, competitive landscape, and risk profile. Rating Pitch – Generates a structured pitch deck covering sector context, rating history, and peer positioning. Sector Analysis – Combines Moody’s proprietary research with live market intelligence to deliver a full sector-level outlook. Each skill encodes analytical steps and quality standards to produce outputs that are consistent, sourced, and defensible for high-stakes decision-making in regulated environments. A skill defines how the work is done; Moody's Model Context Protocol (MCP) servers connect it to the data it runs on. MCP is the open standard that lets an AI agent draw directly on Moody's ratings, research, and risk intelligence, so the outputs are grounded in proprietary data rather than general-purpose web content.

A skill teaches an AI agent how to perform a task to a defined standard, captured in a simple, shareable instruction file. Moody's skills are built on the open SKILL.md format, which originated with Anthropic and has since been adopted by platforms like OpenAI, Microsoft, Google, and Amazon. Because the standard is open, the institutional knowledge encoded in each skill is a durable, portable asset rather than a capability locked to one provider, built once and able to run on any compatible platform.

Moody's plans to expand its library of skills to include credit analysis, lead generation, third-party due diligence, and insurance underwriting – extending its analytical frameworks into more of the high-stakes workflows where financial professionals operate. Each new skill will follow the same open, platform-agnostic standard, ensuring the institutional knowledge remains a durable, portable asset across compatible AI platforms.

To learn more, visit https://www.moodys.com/web/en/us/creditview/blog/moodys-skills.html

About Moody’s Corporation

In a world shaped by increasingly interconnected risks, Moody's (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of approximately 16,000 across more than 40 countries, Moody's gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at moodys.com.

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this document are forward-looking statements and are based on future expectations, plans and prospects for Moody’s business and operations that involve a number of risks and uncertainties. Such statements involve estimates, projections, goals, forecasts, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements. Stockholders and investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements and other information in this document are made as of the date hereof, and Moody’s undertakes no obligation (nor does it intend) to publicly supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise, except as required by applicable law or regulation. Factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under “Risk Factors” in Part I, Item 1A of Moody’s annual report on Form 10-K for the year ended December 31, 2025, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company’s business, results of operations and financial condition.

More News From Moody's Corporation

Back to Newsroom

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (ADC) to be approved in first-line metastatic TNBC in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.

“This approval brings a profound sense of hope to a community that has long been waiting for progress,” said Dr. Javier Cortes, Head of the International Breast Cancer Center, Madrid and Barcelona, Spain. “For women diagnosed with metastatic TNBC, particularly those who are younger, every second counts, and having an effective treatment option that can delay the progression of their disease is invaluable. This is the kind of meaningful advance our community needs.”

For many living with metastatic TNBC, the most aggressive form of breast cancer, first-line therapy may be their only line of treatment, creating an urgent need for effective treatment options to be used as early as possible.

“This approval represents a significant step forward in how we treat people with first-line metastatic TNBC in Europe,” said Mika Kakefuda Derynck, MD, Senior Vice President, Clinical Development, Oncology at Gilead Sciences. “We have long recognized the challenges that patients and clinicians face with this aggressive cancer, and we believe this approval will provide a much-needed new option for people with metastatic TNBC.”

The EC’s marketing authorization is based on data from the Phase 3 ASCENT-03 study which demonstrated a highly statistically significant and clinically meaningful progression-free survival for Trodelvy compared to standard of care chemotherapy as a first-line treatment. In ASCENT-03, Trodelvy demonstrated a 38% reduced risk of disease progression or death in patients who are not candidates for PD-1/PD-L1 inhibitors. The ASCENT-03 study utilized a patient-centered crossover design, which allowed patients in the chemotherapy arm to receive Trodelvy after their disease progressed. The EC’s approval, based on the strength of the PFS data, confirms the study's objective to demonstrate using Trodelvy earlier provides a clinical benefit over chemotherapy for metastatic TNBC patients.

Continued Global Regulatory Filings for Trodelvy in First-Line Metastatic TNBC

Gilead has submitted a supplemental filing to the European Medicines Agency for Trodelvy in combination with Keytruda® (pembrolizumab) for patients with PD-L1 positive unresectable locally advanced or metastatic TNBC, based on data from the Phase 3 ASCENT-04 study. This application is currently under review. If approved, Trodelvy has the potential to be a backbone treatment in 1L metastatic TNBC, across PD-L1 status in Europe. In the U.S., Gilead has also submitted supplemental filings to the Food and Drug Administration (FDA) for Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, or in combination with Keytruda or Keytruda Qlex in patients whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

KEYTRUDA® and KEYTRUDA QLEX™ are trademarks of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

About Triple-Negative Breast Cancer In Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitors

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for approximately 15% of all breast cancers. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited HER2 expression. Due to the nature of TNBC, treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of mBC.

About Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect.

Outside of Europe, Gilead has submitted supplemental applications to the U.S. Food and Drug Administration (FDA) for approval of Trodelvy based on the ASCENT-03 and ASCENT-04 studies.

Healthcare professionals have substantial clinical experience with Trodelvy, with more than 75,000 breast cancer patients treated since 2020. In addition to its first-line indication approval, Trodelvy is currently approved in more than 60 countries for patients with second-line or later mTNBC and in over 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer. It is the only ADC with four positive Phase 3 trials in HER2-negative metastatic breast cancer and the only Trop-2-directed ADC to demonstrate a meaningful overall survival benefit in two distinct types of metastatic breast cancer.

Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across different tumor types, including in small cell lung cancer and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.

U.S. Indications for Trodelvy

TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. U.S. Important safety information FOR TRODELVY
BOXED WARNING: NEUTROPENIA AND DIARRHEA

TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. CONTRAINDICATIONS

Severe hypersensitivity reaction to TRODELVY. WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur as early as the first cycle of treatment and may require dose modification. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities. Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm3 on Day 1 of any cycle or below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 of USPI.

Diarrhea: Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤ Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: TRODELVY can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.

Nausea and Vomiting: TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 64% of all patients treated with TRODELVY and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤ 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.

ADVERSE REACTIONS

In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).

In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.

UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.

Please see full Prescribing Information, including BOXED WARNING.

About Gilead and Kite Oncology

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving Trodelvy; uncertainties relating to regulatory applications and related filing and approval timelines, including such as the pending applications for Trodelvy in 1L mTNBC and potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

U.S. Prescribing Information for Trodelvy, including BOXED WARNING, is available at www.gilead.com.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

More News From Gilead Sciences, Inc.

Shares of SSR Mining (SSRM 4.75%) are building on a massive pop that started last week. The gold stock jumped 5.4% higher as of 1:45 p.m. ET Wednesday, and is up 36% in just one week, as of this writing.

The miner is about to get a windfall from an asset sale, and it has announced something that should make its shareholders happy. Gold, meanwhile, is trending higher.

Image source: Getty Images.

Why are investors buying SSR Mining stock? SSR Mining has made the most of the surge in gold prices. It recently delivered a blowout first quarter, ending it with $600 million in cash, low debt, and $211 million in free cash flow.

After already burning through $300 million to buy back its own stock, the company just announced it's dropping another $500 million on stock buybacks.

That's not all: The gold miner is also reinstating its dividend.

I fully expected SSR Mining to resume share buybacks and dividends. It suspended dividends after a fatal accident at its Copler mine in Turkey in 2024, but now has a firm deal to sell that unproductive mine for $1.5 billion before the end of the third quarter. A good portion of that money is going to go back to shareholders.

Today's Change

(

-4.75

%) $

-1.46

Current Price

$

29.26

SSR Mining stock could fall if this happens, but should you worry? Although $0.03 per share every quarter is a modest payout, the symbolism is huge. A dividend reinstatement and accelerated share buybacks reveal how confident management is about the company's prospects.

And why not? SSR Mining has rarely looked this strong financially. Dumping Copler removes a major overhang, leaving it a much leaner company.

Meanwhile, macro tailwinds are doing their part. Gold has picked up momentum after a precipitous fall. The yellow metal bounced back over $4,300 per ounce today after dropping to a six-month low and almost hitting $4,000 per ounce on June 10. Investors expect a U.S.-Iran peace agreement to help restore oil flows and cool off inflation and interest rate concerns.

Investors, however, should remember that the peace agreement hasn't been finalized. If it falls through, gold could easily slide back.

That, however, shouldn't hurt SSR Mining much unless gold absolutely craters. SSR Mining is in a fantastic spot, using its cash pile to reward shareholders – and that is exactly what investors should focus on.

Palantir Technologies Inc (NYSE:PLTR) has entered into a partnership with Zeta Global aimed at developing a unified data and artificial intelligence infrastructure for marketing applications, a move Wedbush analysts described as another validation point for enterprise AI adoption.

The partnership combines Palantir's Foundry platform with Zeta's Data Cloud and Athena intelligence layer to support data-driven marketing decisions and operational execution.

Under the agreement, Zeta's Data Cloud will be rearchitected on Foundry, allowing enterprise customers to connect governed data with real-time decision-making capabilities.

According to Wedbush, the collaboration seeks to establish a new framework for "agentic marketing," where AI systems can automate and optimize business decisions while maintaining security, governance and compliance standards.

The analysts highlighted Palantir's Ontology technology as a key component of the partnership. Ontology creates a digital representation of an organization's operations by integrating business data and processes, enabling AI applications and workflows to operate within a governed environment.

Wedbush noted that Ontology serves as an intelligence layer that translates raw enterprise data into practical AI use cases and supports the deployment of AI agents and automated decision-making systems.

The firm wrote that marketing has become an important focus area for companies investing in AI technologies as businesses seek tools capable of processing trusted data in real time to improve customer acquisition, retention and engagement.

Zeta operates an AI-powered marketing cloud used by enterprises globally and leverages large volumes of consumer data signals to support marketing activities. Wedbush noted that the partnership is expected to generate more than $100 million in revenue for Zeta over several years.

The analysts believe that  the agreement reinforces Palantir's position within the enterprise AI market and demonstrates growing demand for platforms that connect operational and customer intelligence.

Wedbush maintained its ‘Outperform’ rating on Palantir shares and reiterated its $230 price target, which implies significant upside from current levels of about $116.

Legacy media faces a structural crisis that cannot be solved by simply greenlighting better television shows. Owning premium content means very little if a network does not control how that content physically reaches viewers. Fox Corporation NASDAQ: FOX just acknowledged this harsh reality with a $22 billion cash-and-stock deal to acquire Roku Inc. NASDAQ: ROKU.

FOX Today

$44.55 -0.38 (-0.85%)

As of 06/23/2026 04:00 PM Eastern

52-Week Range$44.17▼

$68.18Dividend Yield1.26%

P/E Ratio11.75

Price Target$75.00

The headline numbers are aggressive, and the immediate market reaction reflects anxiety over the immense financial leverage required to close this deal. Look past the initial shock, though, and a clear survival strategy emerges. By taking ownership of the dominant connected-TV operating system, Fox Corporation transforms from a vulnerable content supplier into a powerful toll-collecting gatekeeper.

Get FOX alerts:

Traditional broadcasters have spent the last decade suffering from margin compression as cable subscriptions have dwindled and affiliate fees have dried up. Transitioning to streaming was supposed to be a life raft, but networks quickly found themselves paying massive distribution cuts to third-party hardware providers just to access viewers. This acquisition signals capitulation to a new industry rule. Content alone cannot survive without distribution control.

Swallowing the Debt to Secure the FutureThe financial architecture of this acquisition requires Fox Corporation to stretch its balance sheet to the absolute limit. The company is executing the buyout at $160 per share, using a 60/40 cash-and-stock split, with $96 in cash and 0.9693 shares of Fox Class A NASDAQ: FOXA common stock per Roku share. To fund the enterprise value, Fox Corporation is securing up to $12 billion in bridge financing and absorbing $8.3 billion in new debt.

When Fox, with a $23 billion market capitalization, purchases a target valued at $22 billion, FOX shareholders are forced to absorb significant equity dilution. The market reaction was swift and punishing. Fox Corporation shares collapsed 17% on heavy volume following the announcement. Institutional investors immediately repriced Fox to account for a post-deal net leverage ratio of 2.8x trailing 12-month EBITDA.

Fox Corporation (FOX) Price Chart for Wednesday, June, 24, 2026

Valuation friction also plays a major role in the sell-off. Fox trades as a mature value play with a price-to-earnings ratio of 14, while Roku trades purely on growth metrics with a towering price-to-earnings ratio of 105. Fusing a legacy cash-flow generator with a high-multiple growth asset creates a complex valuation model that institutional bases often reject in the short term.

Corporate insiders at Roku clearly anticipated this valuation ceiling. Key executives executed a concentrated wave of share liquidations just before the merger announcement. CEO Anthony Wood sold 18,000 shares on June 12, 2026, followed by significant sales from Director Mai Fyfield on June 13, 2026. The strategic timing indicates Roku executives aggressively locked in peak valuations before the cash-and-stock conversion was finalized.

Despite the near-term pain for Fox Corporation shareholders, the debt load is a highly calculated capital expenditure. Management projects $400 million in run-rate cost savings and models the transaction to be accretive to free cash flow per share by the second full year following the anticipated 2027 close. Paying a premium to secure a 100-million-household hardware ecosystem is the cost of permanently escaping the decay of linear television.

Forging the Ultimate Streaming MonopolyFox Corporation already controls Tubi, a rapidly expanding platform in the free ad-supported streaming television sector. Integrating Tubi with The Roku Channel creates an unprecedented digital advertising inventory pool. Management plans to keep the two platforms operating as separate consumer-facing applications, a smart operational move that exploits a minimal 33% audience overlap.

The true economic value is unlocked behind the screen. By merging datasets and ad-tech infrastructure, Fox Corporation captures a dominant share of the free streaming market across global endpoints. Owning the hardware layer allows Fox to weaponize the user interface. When a viewer powers on a Roku television, Fox can dictate the visual real estate. The operating system can be programmed to natively push Fox Sports, Fox News, and Tubi content before competing applications load.

This prioritization guarantees viewership for internal Fox Corporation properties and drastically reduces the customer acquisition costs that plague standalone streaming services. A unified data ecosystem also allows Fox Corporation to track consumer behavior from the moment a television turns on to the second a viewer powers down, creating a highly targeted advertising profile that commands premium ad rates.

Forcing Advertisers to Pay the TollRoku built an empire by operating as a neutral territory. Roku acted as an agnostic aggregator, routing viewers to various streaming apps while taking a standard cut of ad inventory. That neutrality ends the moment the acquisition closes.

Transitioning the living room operating system into a walled garden designed to amplify Fox Corporation's inventory completely disrupts the ad-supported streaming ecosystem. Advertisers and media agencies rely on unbiased auction environments to deploy capital efficiently. If Roku backend ad-bidding logic shifts to favor Fox Corporation network properties, ad buyers will naturally look for alternative platforms to ensure fair market pricing.

This structural shift creates massive tailwinds for independent programmatic operators. Companies operating as independent demand-side platforms and supply-side platforms offer a neutral ground for ad buying and selling. Operators like The Trade Desk NASDAQ: TTD and Magnite NASDAQ: MGNI are structurally insulated from these emerging content conflicts. As the newly consolidated Fox Corporation ecosystem raises the toll for living room access, programmatic advertising budgets will systematically migrate toward the remaining agnostic infrastructure.

The Hunt for Neutral Ad-Tech WinnersThe combined Fox Corporation and Roku entity instantly becomes the third-largest player in U.S. television by viewing share. This consolidation removes the last major independent hardware operator from the board, leaving the sector entirely controlled by legacy media and mega-cap tech conglomerates.

Wall Street analysts are rapidly updating models to reflect this reality. Several firms downgraded Roku to market perform ratings, citing capped upside at the $160 buyout price. Conversely, a select few analysts raised their price targets slightly, pricing in the remote possibility of a competing bid from a tech giant willing to absorb the termination fee to prevent Fox Corporation from controlling the living room gateway.

Holding legacy linear broadcasters that lack a dedicated distribution arm now carries immense structural risk. Successful navigation of this market requires identifying which ad-tech firms and streaming platforms can thrive when independent hardware no longer exists. Investors looking to capitalize on shifting advertising budgets may want to add independent programmatic ad-tech operators to watchlists as the connected-TV ecosystem adjusts to the newest gatekeeper.

Should You Invest $1,000 in FOX Right Now?Before you consider FOX, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FOX wasn't on the list.

While FOX currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Micron stock NASDAQ:MU reports fiscal third-quarter earnings after the US market close on Wednesday, and the options market has already marked the event as a potential shock.

The stock has been one of the biggest AI winners of the year, with gains of more than 800% over the past 12 months and a market value that has pushed above $1 trillion.

That makes tonight’s print a test of whether the AI hardware boom can keep outrunning even the most aggressive expectations.

The options chain was already telling that story before a single number dropped.

Saxo Bank said Micron’s near-term options were pricing in an implied move of about 11% in either direction after earnings.

That does not mean traders are betting the stock will rise 11%. It means the market is attaching a high price to uncertainty.

Based on a reference stock price of $1,172.30, Saxo said the options market was implying a post-earnings range of roughly $1,066 to $1,331.

That is a very wide earnings window, even for a stock that has become central to the AI trade.

The reason is volatility, as Saxo pegged front-week implied volatility at about 155%, compared with roughly 109% for July options.

In plain English, the market is charging a huge premium for options that cover the earnings event.

That creates a risk known as “IV crush”. Once the results are out, that event premium can disappear quickly.

A trader can get the direction right and still lose money if Micron’s actual move is smaller than the move already priced into the option.

For ordinary investors, the message is simpler: the market expects fireworks, but it is not saying which way the blast goes.

The reason traders are willing to price such a large move is that Micron is no longer being treated like a normal memory-cycle stock.

TD Cowen analyst Krish Sankar recently lifted his price target on Micron to $1,500 from $660. The core of his argument was blunt: the role of memory in AI is “structural rather than cyclical”.

That phrase matters as memory stocks have historically moved through boom-and-bust cycles. Prices rise, manufacturers add supply, margins peak, and the cycle eventually rolls over.

Wall Street is now asking whether AI has changed that pattern.

Bank of America’s Vivek Arya also raised his Micron target to $1,500 from $950. The timing was notable because the upgrade came as the stock was selling off.

That made the call less like a momentum chase and more like a statement of conviction.

Other target increases have followed the same direction.

TheStreet cited UBS at $1,625, Needham at $1,550, and several other firms clustered well above the stock’s recent trading range.

The fundamental story is high-bandwidth memory, or HBM. These chips sit alongside advanced AI accelerators and are essential for training and running large models.

Supply remains tight, pricing power has extended, and analysts are increasingly treating Micron as a core AI infrastructure beneficiary rather than a commodity memory maker.

Micron’s own guidance has raised the bar. The company guided for fiscal Q3 revenue of $33.5 billion at the midpoint and gross margin of about 81%.

For a memory chipmaker, that margin level would be extraordinary, but it also leaves little room for disappointment.

LEAWOOD, Kan.--(BUSINESS WIRE)--AMC Entertainment Holdings, Inc. (NYSE: AMC) (“AMC” or “the Company”), announced today that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 95,250,000 shares of AMC common stock. The Offering is expected to result in gross proceeds of approximately $200 million, before deducting agent fees and offering expenses.

AMC intends to use the net proceeds from the Offering to redeem all of its $125,500,000 aggregate principal amount of 6.125% Senior Subordinated Notes due 2027, pay related fees, costs, premiums and expenses associated therewith and for general corporate purposes, which may include the repayment of other debt, the strengthening of AMC's cash reserves and investments to enhance the moviegoing experience at AMC's theatres. The Offering is expected to close on June 24, 2026, subject to customary closing conditions.

Roth Capital Partners is acting as the sole placement agent for the Offering.

The shares described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-293291), originally filed with the Securities and Exchange Commission (the “SEC”) on February 9, 2026. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies may be obtained when available, from Roth Capital Partners, LLC, 888 San Clemente, Suite 400, Newport Beach, CA 92660, (800) 678-9147 or by email at [email protected], or by accessing the SEC’s website, www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AMC Entertainment Holdings, Inc.

AMC is the largest movie exhibition company in the United States, the largest in Europe and the largest throughout the world with approximately 850 theatres and 9,600 screens across the globe. AMC has propelled innovation in the exhibition industry by: deploying its Signature power-recliner seats; delivering enhanced food and beverage choices; generating greater guest engagement through its loyalty and subscription programs, website, and mobile apps; offering premium large format experiences and playing a wide variety of content including the latest Hollywood releases and independent programming. For more information, visit www.amctheatres.com.

Website Information

This press release, along with other news about AMC, is available at www.amctheatres.com. We routinely post information that may be important to investors in the Investor Relations section of our website, www.investor.amctheatres.com. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD, and we encourage investors to consult that section of our website regularly for important information about AMC. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document. Investors interested in automatically receiving news and information when posted to our website can also visit www.investor.amctheatres.com to sign up for email alerts.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In many cases, these forward-looking statements may be identified by the use of words such as “will,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “indicates,” “projects,” “goals,” “objectives,” “targets,” “predicts,” “plans,” “seeks,” and variations of these words and similar expressions. Examples of forward-looking statements include statements the Company makes regarding impacts of the industry box office in North America and European industry attendance, the Company’s expected revenue, net loss, capital expenditures, diluted loss per share, Adjusted EBITDA and estimated cash and cash equivalents, the potential for sustained growth, the Company’s cash generation potential, the potential for further debt equitization, the ability to achieve the Company’s AMC Go Plan, the Company’s financial runway and the continued box office recovery as well as the future box office outlook, including with respect to the full year 2026, the use of proceeds from the Offering, changing market dynamics and capitalizing on opportunities to further strengthen AMC’s balance sheet. Any forward-looking statement speaks only as of the date on which it is made. These forward-looking statements may include, among other things, statements related to AMC’s current expectations regarding the performance of its business, financial results, liquidity and capital resources and are based on information available at the time the statements are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks, trends, uncertainties and other facts that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks, trends, uncertainties and facts include, but are not limited to: the sufficiency of AMC’s existing cash and cash equivalents and available borrowing capacity; AMC’s ability to obtain additional liquidity, which if not realized or insufficient to generate the material amounts of additional liquidity that will be required unless it is able to achieve more normalized levels of operating revenues, likely would result with AMC seeking an in-court or out-of-court restructuring of its liabilities; the effectiveness of the refinancing transactions completed in the third quarter of 2025 and the ability to further equitize existing debt; increased use of alternative film delivery methods or other forms of entertainment; the continued recovery of the North American and international box office; AMC’s significant indebtedness, including its ability to meet its covenants and limitations on AMC's ability to take advantage of certain business opportunities imposed by such covenants; shrinking exclusive theatrical release windows; the seasonality of AMC’s revenue and working capital; intense competition in the geographic areas in which AMC operates; risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges; motion picture production, promotion, marketing, and performance including labor stoppages affecting the production, supply and release schedule of theatrical motion picture content and choice of distributors to release fewer feature-length films as a result of the additional financial burden imposed by tariffs; the use of artificial intelligence (“AI”) technology in the filmmaking process and audience acceptance of movies made utilizing AI technology; general and international economic, political, regulatory and other risks, including but not limited to rising interest rates; AMC’s lack of control over distributors of films; limitations on the availability of capital, including on the authorized number of AMC common stock; dilution of voting power caused by recent sales of AMC common stock and through the issuance of AMC common stock underlying Muvico LLC’s exchangeable notes and the issuance of preferred stock; AMC’s ability to achieve expected synergies, benefits and performance from its strategic initiatives; AMC’s ability to refinance its indebtedness on favorable terms; AMC’s ability to optimize its theatre circuit; AMC’s ability to recognize interest deduction carryforwards, net operating loss carryforwards, and other tax attributes to reduce future tax liability; supply chain disruptions, labor shortages, increased cost and inflation; and other factors discussed in the reports AMC has filed with the SEC. Should one or more of these risks, trends, uncertainties, or facts materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by the forward-looking statements contained herein. Accordingly, the Company cautions you against relying on forward-looking statements, which speak only as of the date they are made.

Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. For a detailed discussion of risks, trends and uncertainties facing AMC, see the section entitled “Risk Factors” and elsewhere in the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as the Company’s other filings with the SEC, copies of which may be obtained by visiting the Company’s Investor Relations website at investor.amctheatres.com or the SEC’s website at www.sec.gov.

AMC does not intend, and undertakes no duty, to update any information contained herein to reflect future events or circumstances, except as required by applicable law.

More News From AMC Entertainment Holdings, Inc.

Key Takeaways Amgen's biosimilar portfolio generated $835 million in Q1 2026 sales, up 14% year over year.New launches like Wezlana and Pavblu are helping offset declines in older biosimilar products.AMGN is advancing biosimilars to Opdivo, Keytruda and Ocrevus to tap major biologic markets. Historically known for its innovative biologic medicines such as Enbrel, Prolia and Repatha, Amgen (AMGN - Free Report) has also emerged as one of the global leaders in biosimilars. The company boasts a strong biosimilars portfolio and the business has become an increasingly important contributor to the company's top-line growth strategy. Its biosimilar portfolio spans oncology, inflammation and rare diseases.

Some of Amgen's older biosimilars — Kanjinti (a biosimilar of Roche’s [(RHHBY - Free Report) ] Herceptin), Mvasi (a biosimilar of Roche’s Avastin), Riabni (a biosimilar to Roche’s Rituxan), Avsola (a biosimilar to J&J’s [(JNJ - Free Report) ] Remicade) and Amjevita/Amgevita (a biosimilar of AbbVie’s Humira) — are seeing slowing/declining sales due to rising competitive pressure.

To combat the impact, Amgen has successfully launched biosimilars of J&J’s Stelara, called Wezlana, AstraZeneca’s (AZN - Free Report) Soliris, called Bekemv, and Regeneron’s Eylea, called Pavblu, in the past couple of years.

In the first quarter of 2026, its biosimilar products generated sales of $835 million, up 14% year over year, including $47 million from Wezlana and $280 million from Pavblu. Since the first launch in 2018, Amgen’s biosimilar drugs have delivered more than $14 billion in sales, significantly contributing to top-line growth and generating meaningful cash flows.

Amgen is also developing biosimilars referencing some of the pharmaceutical industry's largest biologics. Phase III studies are ongoing to evaluate biosimilar versions of Bristol-Myers’ Opdivo (ABP 206), Merck’s Keytruda (ABP 234) and Roche’s Ocrevus (ABP 692). These medicines collectively generate tens of billions of dollars in annual sales globally. As patents on these products expire over the next several years, biosimilars targeting them could create substantial revenue opportunities for Amgen.

Over the next few years, Amgen will face a significant patent-expiration overhang. Its own key branded products, such as Prolia, Xgeva, Enbrel and Otezla, have either already lost exclusivity or are expected to do so within the next few years. Together, these medicines accounted for roughly 30% of Amgen’s 2025 product sales, leaving the company exposed to potential revenue pressure from generic and biosimilar competition as patents expire.

Amgen’s new biosimilar launches will play a key role in mitigating the impact of LOE over the next few years, along with Amgen’s key growth drivers, which include Repatha, Evenity, Tezspire and some oncology and rare disease drugs.

While Amgen's biosimilars may not individually achieve blockbuster status comparable to leading innovative therapies, together they represent a meaningful source of recurring revenues, enhance portfolio diversification and provide access to some of the world's largest biologic markets. Over the long term, the biosimilars business is expected to remain a key pillar of Amgen's strategy, supporting a more diversified, resilient and sustainable growth profile.

AMGN’s Price Performance, Valuation and EstimatesAmgen’s stock has risen 5.3% so far this year compared with an increase of 1.3% for the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 15.02 forward earnings, which is lower than 17.05 for the industry. The stock is also trading above its five-year mean of 13.81.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for earnings has risen from $22.21 per share to $22.26 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has risen from $23.35 to $23.70 per share over the same timeframe.

Image Source: Zacks Investment Research

Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways MELI is rapidly expanding its first-party business to boost assortment and pricing competitiveness.MELI's first-party growth is increasing logistics, warehousing and inventory management demands.MELI continues prioritizing market-share gains as margin recovery remains challenging. MercadoLibre's (MELI - Free Report) aggressive expansion of its first-party (1P) business is emerging as a key headwind to margin recovery. While the strategy is strengthening assortment, improving pricing competitiveness and helping the company gain share across key categories, the rapid scaling of inventory-led commerce is introducing structural profitability pressures that could weigh on operating leverage for longer than anticipated.

The company's 1P gross merchandise volume grew 69% year over year on a foreign exchange-neutral basis in the first quarter of 2026, significantly outpacing overall marketplace growth. The strategy has been particularly effective in consumer electronics, where MercadoLibre has expanded its competitive position through broader selection and sharper pricing. However, unlike the higher-margin third-party marketplace model, 1P requires inventory ownership, procurement spending and greater fulfillment intensity. As the business scales, associated logistics, warehousing and inventory management costs are likely to rise alongside volume growth, creating a more capital-intensive operating profile.

Gross margin contracted 300 basis points year over year in the first quarter of 2026, with rapid 1P expansion among the key drivers of the decline. Although profitability within certain mature 1P categories has improved, the broader business continues to absorb a growing share of corporate allocations as it scales faster than the overall marketplace. This dynamic suggests margin dilution will likely persist even as scale benefits gradually emerge.

MercadoLibre appears willing to continue prioritizing market-share gains and ecosystem expansion over near-term earnings optimization. As 1P continues to outpace the broader marketplace and absorb a growing share of corporate costs, the path toward margin normalization is expected to remain challenging.

MELI Faces Stiff CompetitionMELI faces stiff competition from Amazon (AMZN - Free Report) and Alibaba (BABA - Free Report) , both of which have expanded logistics and inventory-led commerce capabilities to strengthen user engagement and pricing competitiveness.

Amazon continues to scale its first-party retail network despite persistent fulfillment cost pressures, and its scale advantage sets a high bar for efficiency. Alibaba has likewise increased investments across direct retail and supply-chain infrastructure, navigating similar margin trade-offs as it defends its share.

Unlike Amazon and Alibaba, MELI is expanding 1P while simultaneously ramping fintech, free shipping and logistics spend, which could keep profitability under pressure for longer.

MELI’s Share Price Performance, Valuation and EstimatesMELI shares have declined 18.8% in the year-to-date (YTD) period, and the Zacks Internet–Commerce industry and the Zacks Retail-Wholesale sector have declined 4.5% and 0.9%, respectively.

MELI’s YTD Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, MELI is currently trading at a forward 12-month Price/Sales ratio of 1.83X compared with the industry’s 1.99X. MELI has a Value Score of F.

MELI's Valuation
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for MELI’s 2026 earnings is pegged at $40.97 per share, indicating a 3.98% year-over-year increase.

An updated edition of the April 28, 2026 article.

Corporate leadership is evolving as an increasing number of women take on senior roles at publicly traded companies. This shift is being supported by business results, with many women-led organizations demonstrating strong innovation, operational adaptability and solid shareholder returns across a range of industries. These leadership appointments go beyond symbolism, as many of these executives are outperforming peers through disciplined execution, efficient capital allocation and a clear focus on long-term value creation, strengthening investor confidence in more resilient and sustainable business models.

The latest reports paint a nuanced picture: women are becoming a structural force in U.S. entrepreneurship, even as funding and systemic gaps persist. One of the clearest takeaways is scale. Women now own more than 40% of all U.S. businesses, employing roughly 12.6 million people and generating $2.8 trillion in revenues. Growth has also been faster than that of male-owned firms, with women-owned businesses expanding nearly twice as quickly between 2022 and 2025. This shift signals that female entrepreneurship is no longer niche—it is central to the U.S. small- and mid-sized business ecosystem, particularly in services, consumer, healthcare and increasingly tech-enabled sectors. The data suggests women are not just starting companies, but building durable, employment-generating enterprises, a key driver of long-term economic resilience.

Female founders are increasingly gaining traction in AI and next-generation technology markets, which have become the primary destinations for venture capital. This indicates a shift from traditional sectors into high-value, innovation-driven markets, positioning women at the center of future growth themes. According to PitchBook's 2025 Female Founders report, U.S. female-founded startups raised a record $73.6 billion in venture capital in 2025, representing 27.7% of total U.S. VC deal value, the highest share on record. Importantly, AI accounted for roughly two-thirds of all venture dollars invested in female-founded startups.

At the same time, capital is becoming more concentrated in fewer, larger deals—often in AI—suggesting that while top-tier female-led companies are scaling rapidly, broader participation remains uneven.

Despite strong progress, a significant funding gap continues to limit the full potential of female founders. All-female founding teams still receive only about 1–2% of total U.S. venture capital, even though evidence suggests they often deliver higher capital efficiency and competitive returns. This imbalance highlights a structural constraint within the venture ecosystem, where access to early-stage and growth funding remains uneven. As a result, many promising female-led startups may struggle to scale at the same pace as their peers, underscoring a sizable untapped opportunity for investors willing to address this gap.

Despite funding challenges, women-led companies continue to drive innovation and resilience, making them attractive investment opportunities. If you want to capitalize on it, our Women Run Companies Screen will help you spot high-potential stocks in this space.

Investors looking to capitalize on opportunities across diverse industries should consider Newmont Corporation (NEM - Free Report) in gold mining, Pitney Bowes Inc. (PBI - Free Report) in shipping and mailing technology, The Coca-Cola Company (KO - Free Report) in the global beverage industry, Apple (AAPL - Free Report) in consumer technology and digital services, and Occidental Petroleum Corporation (OXY - Free Report) in the energy sector. These companies demonstrate strong leadership and strategic vision within their respective industries, positioning them for long-term growth and value creation.

Ready to uncover more transformative thematic investment ideas? Explore 37 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.

Newmont: Since joining Newmont in 2023 as chief operating officer and later becoming president and CEO in January 2026, Natascha Viljoen has played a key role in strengthening the company’s operational performance and strategic focus. One of her most important contributions has been overseeing the integration and optimization of Newmont’s expanded asset portfolio following the acquisition of Newcrest Mining. Under her leadership, the company has emphasized operational discipline, asset rationalization and productivity improvements to enhance profitability and cash generation across its global mining operations.

Viljoen has also been instrumental in advancing Newmont’s value-over-volume strategy. Rather than pursuing production growth at any cost, she has focused on improving margins, maximizing returns from high-quality assets and streamlining the company’s portfolio. Newmont has announced plans to divest non-core operations and concentrate capital on its Tier 1 assets, a move designed to strengthen the balance sheet and improve long-term shareholder returns. Her deep technical and operational background has helped drive initiatives aimed at improving mine performance, safety standards and cost efficiency.

Viljoen’s leadership is particularly important as the gold mining industry faces rising cost pressures, stricter environmental expectations and increasing capital allocation scrutiny. Her focus on operational excellence, disciplined capital spending and portfolio optimization positions Newmont to generate stronger free cash flow across commodity cycles. As the first woman to lead the company, Viljoen also brings a fresh leadership perspective while maintaining continuity in Newmont’s long-term strategy. Currently, Newmont sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Pitney Bowes: Debbie Pfeiffer has been one of the key leaders behind the stability and growth of Pitney Bowes’ Presort Services business, a segment that remains central to the company's cash flow generation and customer relationships. As executive vice president and president of Presort Services, she oversees a nationwide network of 35 operating centers and has played an important role in expanding the scale and efficiency of the business. With more than two decades at Pitney Bowes and over 40 years of industry experience, Pfeiffer has helped strengthen customer retention, expand national accounts and improve operating execution across the presort network.

Her contribution is particularly important because Presort Services is one of Pitney Bowes’ most resilient businesses. Under her leadership, the company has continued investing in automation and network expansion to improve service quality and processing efficiency. A recent example is the opening of a new highly automated Presort Services facility in Phoenix, AZ, which significantly increases processing capacity and supports faster mail delivery while lowering costs for customers. In 2025, the Presort network handled more than 15 billion pieces of mail, highlighting the scale of the operation she manages.

Her leadership also aligns with Pitney Bowes’ broader effort to improve profitability and operational performance. Following the company’s first-quarter 2026 results, management continued to emphasize operational efficiency, cash generation and strategic investments in core businesses. The Presort segment remains a valuable asset because it generates recurring revenue, benefits from long-standing customer relationships and provides economies of scale that are difficult for competitors to replicate. Pfeiffer’s ability to drive network optimization, customer growth and cost efficiencies makes her a significant contributor to Pitney Bowes’ long-term earnings and free-cash-flow profile. Currently, Pitney Bowes sports a Zacks Rank #1.

Coca-Cola: Tapaswee Chandele has become a key figure in Coca-Cola’s leadership team after being named executive vice president and global chief people officer in 2026. Having spent more than 25 years with the company, she has helped shape Coca-Cola’s approach to talent development, leadership succession and workforce strategy. Prior to her current role, she led Global Talent, Development and HR System Partnerships, overseeing programs designed to identify, develop and retain future leaders across the organization. Her leadership experience across India, Türkiye, South Africa and the United States has provided her with broad insight into Coca-Cola’s diverse global operations.

Chandele’s impact goes well beyond managing human resources. She has played an important role in strengthening leadership benches, enhancing employee capabilities and supporting organizational change initiatives across the company. Her elevation to the executive leadership team reflects Coca-Cola’s belief that attracting and developing talent is essential to maintaining its competitive position. Given the company’s vast global footprint, effective workforce management and leadership development are critical to driving consistent execution across markets.

Chandele’s role has become increasingly important as Coca-Cola pursues growth opportunities while navigating evolving consumer trends and advancing its digital capabilities. The company has continued to deliver solid organic revenue growth and healthy profitability, supported by strong execution across its global system. As global chief people officer, she is responsible for ensuring that Coca-Cola has the talent, leadership depth and organizational structure needed to support these objectives. Her efforts to build a stronger workforce and leadership pipeline could help sustain operational excellence and long-term value creation. Currently, Coca-Cola carries a Zacks Rank #2 (Buy).

Apple: Deirdre O’Brien has become one of Apple’s most influential executives through her dual role as senior vice president of Retail + People. Reporting directly to CEO Tim Cook, she oversees Apple’s global retail stores, online sales operations and human resources functions. This combination gives her significant influence over both customer engagement and workforce strategy. O’Brien has played a key role in shaping Apple’s retail experience, ensuring that product launches, service offerings and customer support remain consistent with the company’s premium brand positioning. She has also been involved in every major Apple product launch during her nearly four-decade tenure with the company.

From an operational standpoint, O’Brien’s contribution extends beyond retail execution. She leads talent management, recruiting, leadership development, compensation and employee support programs, helping Apple maintain a strong corporate culture while managing a workforce that supports millions of customers worldwide. Her focus on connecting employees, processes and customers has helped Apple preserve high levels of customer satisfaction and employee engagement despite its massive global scale. In an environment where technology companies compete aggressively for talent, her leadership is an important factor in Apple’s ability to attract and retain skilled employees.

Her impact is particularly relevant as Apple continues to deliver strong financial performance. In fiscal second-quarter 2026, Apple reported a record March-quarter revenue of $111.2 billion, up 17% year over year, while earnings per share rose 22% to $2.01. The company also achieved an all-time high in Services revenues and recorded double-digit growth across every geographic segment. Apple’s extensive retail network remains a critical channel for product sales, customer acquisition and ecosystem engagement, making O’Brien’s leadership an important contributor to the company’s long-term growth strategy and brand strength. Currently, Apple carries a Zacks Rank #2.

Occidental: Sylvia Kerrigan has become one of Occidental’s most influential executives through her role as senior vice president and chief legal officer. As the company’s top legal leader, she oversees global legal affairs, corporate governance, compliance and regulatory matters across Occidental’s oil and gas, chemicals and carbon management businesses. Her role is particularly important because Occidental operates in highly regulated markets where legal oversight, environmental compliance and transaction execution directly affect shareholder value. She also serves as a key adviser to the board and senior management on strategic decisions and risk management.

Kerrigan’s contribution has been especially relevant during Occidental’s transformation into a broader energy and carbon management company. The company has pursued major acquisitions, expanded its carbon capture initiatives through its subsidiary 1PointFive and continued optimizing its portfolio while managing a sizable asset base across the United States and international markets. Effective legal and governance oversight is critical to executing these initiatives, securing permits, managing contractual obligations and reducing regulatory risks. Her leadership helps ensure that strategic projects move forward while maintaining compliance with evolving environmental and energy regulations.

Her role also supports Occidental’s financial objectives. In the latest reported quarter, the company generated solid operating cash flow despite commodity-price volatility, supported by strong production from its oil and gas assets and steady contributions from its chemicals business. As Occidental continues to balance capital returns, debt management and investments in low-carbon technologies, Kerrigan’s expertise in governance, compliance and transaction execution remains an important enabler of long-term value creation. Her ability to help navigate legal complexities and regulatory challenges strengthens Occidental’s operational resilience and supports the successful execution of its long-term growth strategy. Currently, Occidental carries a Zacks Rank #2.

APA (APA - Free Report) closed at $33.03 in the latest trading session, marking a -2.65% move from the prior day. The stock's change was less than the S&P 500's daily gain of 1.09%. Elsewhere, the Dow saw an upswing of 0.14%, while the tech-heavy Nasdaq appreciated by 1.91%.

Prior to today's trading, shares of the oil and natural gas producer had lost 13.71% lagged the Oils-Energy sector's loss of 7.57% and the S&P 500's gain of 0.29%.

Market participants will be closely following the financial results of APA in its upcoming release. On that day, APA is projected to report earnings of $1.79 per share, which would represent year-over-year growth of 105.75%. Alongside, our most recent consensus estimate is anticipating revenue of $2.5 billion, indicating a 4.39% downward movement from the same quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.6 per share and a revenue of $9.29 billion, representing changes of +48.54% and +0.75%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for APA. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.55% upward. APA is holding a Zacks Rank of #3 (Hold) right now.

Investors should also note APA's current valuation metrics, including its Forward P/E ratio of 6.06. This expresses a discount compared to the average Forward P/E of 9.26 of its industry.

The Oil and Gas - Exploration and Production - United States industry is part of the Oils-Energy sector. This industry, currently bearing a Zacks Industry Rank of 108, finds itself in the top 45% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing

FDA accepted NDA under Priority Review with a target action date in November 2026; European Commission decision anticipated in the second half of 2027

TARRYTOWN, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the regulatory applications for cemdisiran to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA will review the New Drug Application (NDA) under Priority Review with a target action date in November 2026, following use of a Priority Review Voucher. A decision from the European Commission is anticipated in the second half of 2027.

The submissions are supported by data from the Phase 3 NIMBLE trial evaluating cemdisiran, dosed subcutaneously every 12 weeks, in adults with symptomatic gMG who may be receiving standard of care immunosuppressants based on the investigator’s discretion. Full data from NIMBLE, which is one of the largest global, interventional gMG trials conducted to date, were simultaneously published in The Lancet and presented at the American Academy of Neurology (AAN) Annual Meeting in April 2026. A regulatory filing in Japan is also planned for early 2027.

MG is a rare and chronic autoimmune disease where abnormal anti-AChR antibodies activate the complement system including C5, disrupting communication between nerves and muscles that results in debilitating and potentially life-threatening muscle weakness. Worldwide, an estimated 150 to 200 out of every million people have MG. In the U.S., the disease impacts approximately 85,000 people. Initial manifestations are usually ocular, but approximately 85% of MG patients experience progression to additional disease manifestations, which is then categorized as generalized MG. For these patients, the disease affects muscles throughout the body, resulting in extreme fatigue and difficulties with facial expression, speech, swallowing and mobility. For patients living with gMG, many continue to experience challenges with disease management including treatments that only address symptoms, long-term burden of immunosuppressants, lack of responsiveness as well as waning effectiveness, which can all affect their quality of life.

The safety and efficacy of cemdisiran, as well as its potential use for the treatment of gMG, are investigational and have not been fully evaluated or approved by any regulatory authority.

Regeneron is solely responsible for the development, manufacturing, and commercialization of cemdisiran as a monotherapy and in combination with C5 antibodies through a worldwide licensing agreement with Alnylam.

About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies.

Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes REGEN-COV® (casirivimab and imdevimab), Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab).

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation cemdisiran (an investigational siRNA therapeutic targeting C5); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including cemdisiran for the treatment of adults with generalized myasthenia gravis in the United States and/or European Union as discussed in this press release as well as cemdisiran as a monotherapy or in combination with pozelimab (a C5 antibody) for the treatment of other complement-mediated disorders (including paroxysmal nocturnal hemoglobinuria and/or geographic atrophy secondary to age-related macular degeneration); uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as cemdisiran and pozelimab); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as cemdisiran and pozelimab) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended March 31, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Cerebras Systems CBRS remained in focus Monday after Wedbush reiterated its Outperform rating and $270 price target ahead of the AI chipmaker's first quarterly earnings release as a public company.

Wedbush said demand conditions for Cerebras appear supportive, citing the company's commercial relationships with OpenAI and Amazon. The firm noted that future results may depend more on operational execution and production scaling than customer demand.

Cerebras, which debuted on the Nasdaq in May, is developing large-scale AI processors and computing infrastructure. Wedbush said manufacturing capacity from Taiwan Semiconductor Manufacturing (TSM) could provide an opportunity for higher-than-expected output over the next two years.

The brokerage also pointed to potential benefits from the company's next-generation WSE-4 processor, which market observers expect could enter production in late 2026 or early 2027. Any updates related to that roadmap may be viewed favorably by investors.

Wedbush added that growing demand for AI inference computing, combined with industry supply constraints, could support Cerebras' longer-term expansion efforts as it seeks a larger position in the AI accelerator market.

The likes of Nvidia (NVDA) and Micron (MU) remain the front and center of all AI-related debates in 2026, but billionaire investor Philippe Laffont is approaching the boom from a different angle.

Speaking recently with CNBC, the founder of Coatue Management revealed his $90 billion hedge fund prefers a classic “picks-and-shovels” strategy rather than wagering on individual chipmakers like NVDA.

His preferred means of gaining exposure to AI include TSMC, Lam Research, and Applied Materials Inc – the foundational silicon factories that every semiconductor company relies on.  

Laffont owns TSMC stock for one simple reason: no matter who designs the next breakthrough AI chip, they must go through Taiwan Semiconductor Manufacturing.

For example, Amazon is deploying its custom Trainium silicon, Alphabet Inc is committed to its Tensor Processing Units (TPUs), and a wave of agile startups is entering the GPU space.

Yet, as Laffont points out, “All of them at the end of the day will need the same machines” – and almost all of them depend on TSMC’s cutting-edge foundry nodes to manufacture their silicon.

Holding a sizable stake in TSMC allows Coatue to remain agnostic in the fiercely competitive chip race while steadily capturing the rewards of a capex cycle that shows no signs of slowing down.

To build the microscopic, hyper-dense architectures required for modern AI workloads, specialized hardware is mandatory.

This reality leads Philippe Laffont directly to Lam Research Corp – an industry giant dominant in etching and deposition technology.

Modern artificial intelligence infrastructure is shifting into what the tech investor calls the “agentic era,” in which autonomous software agents execute long, multi-layered workflows.

This technological pivot needs huge amounts of high-bandwidth memory (HBM) and specialized advanced packaging – and LRCX manufactures the precise capital equipment needed to etch deep, flawless vertical pathways in advanced memory chips.

For Laffont, owning Lam Research shares provides a direct window into the physical layer of the AI ecosystem, capturing reliable revenue from every tech company building out data centers.

Completing Laffont’s top trio of semiconductor capital equipment holdings is Applied Materials, the world's largest supplier of tools used to fabricate advanced microchips.

As global electronics manufacturing becomes increasingly localized, AMAT shares benefit from massive structural headwinds and government subsidies.

Laffont – an MIT graduate and notable alumnus of Julian Robertson’s Tiger Management – values the company’s near-monopoly on materials engineering solutions.

“If I’m a supplier to the fabs, I don’t need to make an exact bet on which of the chips is going to win,” he explained.

This strategic diversification protects Coatue Management’s portfolio from rapid obsolescence cycles while giving investors exposure to the hyper-growth of global AI factory expansions.

Note that all three names on Philippe Laffont’s list pay a dividend as well.

Abbott (ABT - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this maker of infant formula, medical devices and drugs have returned +0.5%, compared to the Zacks S&P 500 composite's +0.1% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has lost 3.7%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Abbott is expected to post earnings of $1.28 per share, indicating a change of +1.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $5.48 for the current fiscal year indicates a year-over-year change of +6.4%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $6.05 indicates a change of +10.5% from what Abbott is expected to report a year ago. Over the past month, the estimate has changed -0.2%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Abbott.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Abbott, the consensus sales estimate of $12.53 billion for the current quarter points to a year-over-year change of +12.4%. The $50.49 billion and $55.01 billion estimates for the current and next fiscal years indicate changes of +13.9% and +9%, respectively.

Last Reported Results and Surprise HistoryAbbott reported revenues of $11.16 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $1.15 for the same period compares with $1.09 a year ago.

Compared to the Zacks Consensus Estimate of $11.02 billion, the reported revenues represent a surprise of +1.31%. The EPS surprise was +0.88%.

Over the last four quarters, Abbott surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

In the latest close session, Eli Lilly (LLY - Free Report) was down 1.19% at $1,098.78. The stock fell short of the S&P 500, which registered a gain of 1.09% for the day. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq gained 1.91%.

The stock of drugmaker has risen by 9.14% in the past month, leading the Medical sector's gain of 3.16% and the S&P 500's gain of 0.29%.

The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcoming release. The company is forecasted to report an EPS of $9.01, showcasing a 42.79% upward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $20.44 billion, up 31.39% from the year-ago period.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $35.67 per share and revenue of $85.6 billion. These totals would mark changes of +47.34% and +31.33%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for Eli Lilly. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.06% lower. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).

Digging into valuation, Eli Lilly currently has a Forward P/E ratio of 31.17. This denotes a premium relative to the industry average Forward P/E of 15.47.

Also, we should mention that LLY has a PEG ratio of 1.22. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.6 as trading concluded yesterday.

The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 97, positioning it in the top 40% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Eli Lilly (NYSE:LLY | LLY Price Prediction) just reported a quarter that should have sent bulls into a frenzy. Revenue grew 55.5% year over year to $19.80 billion, Mounjaro alone delivered $8.66 billion, and management raised full-year guidance to $82 to $85 billion.

Yet shares are up just 2.57% year to date at $1,098.57. That disconnect is the entire setup for my question: can LLY trade at $1,200 by year-end 2026? I think it can, and the math is closer than most realize.

What’s Holding Eli Lilly Back Right Now The near-term price action has been ugly. LLY is down 5.37% over the past week after touching $1,160.95 on June 11. The one-month picture is better at +7.55%, but the year-to-date number tells the story of a stock stuck in neutral despite booming fundamentals.

The market worries about pricing. Realized prices fell 13% in Q1 as Mounjaro’s addition to China’s NRDL formulary compressed international margins. Lilly also absorbed $584 million in acquired IPR&D charges from its M&A spree.

Add in 11 recent insider transactions skewed toward selling, and you understand the hesitation. With a beta of 0.517, this should be a steady compounder. Right now it is waiting for a catalyst.

Wall Street Sees Roughly 11% Upside. Our Model Sees More The consensus target sits at $1,215.79, supported by 6 Strong Buy, 18 Buy, 5 Hold, 1 Sell and 1 Strong Sell ratings. That works out to 77% bullish. Our internal model is more aggressive. The base case lands at $1,279.62, implying 16.48% upside, with a bull scenario of $1,334.55 and a bear case of $1,062.97. Confidence on the base case is 90%.

Analysts underweight two things: the speed of the Foundayo (oral GLP-1) ramp and retatrutide’s optionality. Barclays already telegraphed where this could go, maintaining a Buy rating with a $1,400 price target. With earnings growth contributing positively to our 247Factor and bullish consensus at 77%, the $1,200 line looks like a floor.

The Path to $1,200 Per Share Reaching $1,200 from today’s price of $1,098.57 requires a gain of 9.2%. With forward EPS of $35.47, a price of $1,200 implies a forward P/E of 34x. Our base case of $1,279.62 already implies 37x, meaning $1,200 sits below our base case multiple and demands no incremental rerating. The stock simply needs to grow into the earnings.

CEO David Ricks framed it on the Q1 call: “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion. A key milestone was the U.S. FDA approval of Foundayo.”

Early launch metrics are striking: 8,000+ prescribers and 20,000+ patients in weeks, with 80% of scripts new-to-class. Retatrutide’s Phase 3 readout showing weight loss of 25 to 37 pounds and the retatrutide late-stage trial results comparable to or exceeding Zepbound fuel the model. The primary risk remains continued price erosion outpacing volume gains.

Where Eli Lilly Trades Today vs Its Earnings Power At $1,098.57, LLY trades at roughly 31x forward EPS of $35.47. For a business compounding revenue at 28% at the 2026 guidance midpoint with a forward PE of 31x, that looks reasonable. Shares sit 3% below the 52-week high of $1,182.73 and 77.4% above the $619.40 low. The 10-year return of 1,661.56% shows what happens when this company gets a platform right. Today it has two.

Is $1,200 Realistic? Here’s My Take The $1,200 target requires a 9.2% gain from here, and my model’s base case already overshoots it. I view $1,200 by year-end 2026 as realistic.

Three things need to keep going right: Foundayo’s prescriber base must expand, retatrutide’s June obesity readout must confirm the diabetes data, and Q2 must validate the raised guidance. What derails it is sharper-than-expected pricing reset on Mounjaro and Zepbound in the back half. We’ve outlined the blueprint for how Eli Lilly could reach $1,200 in 2026.